Rapid Disease Progression of Advanced Non-small Cell Lung Cancer Five Months after Cessation of Pembrolizumab.
We report a case of late-onset hyperprogressive disease after cessation of a PD-1 inhibitor. A male was diagnosed with metastatic lung adenocarcinoma with little progression for 2 months before treatment. He received pembrolizumab as a second-line treatment and was subsequently prescribed docetaxel for 3 months until a slight increase in pleural effusion. At the time of progression to docetaxel, he commenced prednisolone because of immune-system-related diarrhea. After that, his general condition rapidly worsened with severe fatigue and hypoxia. Computed tomography revealed a massive increase of pleural effusion and replacement of almost the entire liver with cancer over a period of 5 weeks.
PMID: 33106698 [PubMed - in process]
Source: Acta Med Okayama - Category: Universities & Medical Training Authors: Hirabae A, Ichihara E, Sunami R, Ota M, Iwamoto Y, Maeda Y, Kiura K Tags: Acta Med Okayama Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | CT Scan | Docetaxel | Liver | Lung Cancer | Non-Small Cell Lung Cancer | Prednisolone | Taxotere | Universities & Medical Training | Urology & Nephrology